MBRX · Moleculin Biotech, Inc.
AI read · Good for MBRX
The AI's read
This gives Moleculin an encouraging early sign for its lead drug. The result comes from cancer models, not patients, so it does not show that the treatment helps people.
Moleculin Biotech shared new research showing that its drug Annamycin helped pancreatic cancer models live longer.
Good for MBRX
Moleculin reported longer survival in pancreatic cancer models when Annamycin was paired with PD-1 blockade than with either treatment alone. This is encouraging early evidence, but it is not a result in patients.
Get alerts for MBRX
Follow Moleculin Biotech, Inc. (MBRX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MBRXFree on the App Store and Google Play, or on the web.